<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02184832</url>
  </required_header>
  <id_info>
    <org_study_id>2014P001226</org_study_id>
    <nct_id>NCT02184832</nct_id>
  </id_info>
  <brief_title>Dietary Intake of Tryptophan and Metformin Response</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the influence of dietary intake of tryptophan on response to
      metformin. The investigators hypothesize that dietary tryptophan alteration will influence
      metformin response.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in fasting glucose</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in tryptophan concentration</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>tolerability of dietary tryptophan alteration</measure>
    <time_frame>2 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Metformin Response</condition>
  <condition>Fasting Glucose</condition>
  <condition>Tryptophan Concentration</condition>
  <condition>Metformin Concentration</condition>
  <condition>Diet Tolerability</condition>
  <arm_group>
    <arm_group_label>Low tryptophan diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 days of a low tryptophan diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High tryptophan diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 days of a high tryptophan diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>2 doses of 500 mg metformin given approximately 12 hrs apart</description>
    <arm_group_label>Low tryptophan diet</arm_group_label>
    <arm_group_label>High tryptophan diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low tryptophan diet</intervention_name>
    <arm_group_label>Low tryptophan diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High tryptophan diet</intervention_name>
    <arm_group_label>High tryptophan diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. healthy adult male or non-pregnant female volunteers (age 20-40)

          2. able and willing to give consent

        Exclusion Criteria:

          1. Age less than 20 or greater than 40

          2. Women who are pregnant, nursing, or at risk of becoming pregnant

          3. Body mass index (BMI) less than 20 or greater than 28

          4. Changes of more than 5 pounds in weight (increase or decrease) during the month prior
             to enrollment in the study

          5. Participation in more than 300 minutes of exercise per week during the month prior to
             enrollment in the study

          6. Known diabetes or pre-diabetes (based on prior diagnoses, use of medications to lower
             glucose; or fasting blood glucose &gt; 100mg/dL at screening)

          7. Untreated hypertension (defined as systolic blood pressure &gt; 140mmHg and diastolic
             blood pressure &gt; 90mmHg)

          8. Current or past mood disorder, including major depression, anxiety, or bipolar
             disorder

          9. Conditions causing intestinal malabsorption, including celiac disease or a history of
             intestinal or gastric bypass surgery

         10. History of liver disease and/or aspartate aminotransferase (AST) or alanine
             aminotransferase (ALT) more than 3 times upper limit of normal (ULN)

         11. Estimated glomerular filtration rate (eGFR) &lt; 60 ml/min/1.73 m2 as calculated by the
             Modification of Diet in Renal Disease equation

         12. Currently taking or intending to take during the study duration any medication known
             to affect glycemic parameters, such as glucocorticoids, growth hormone, or
             fluoroquinolones

         13. Use of medications and herbal or vitamin supplements during the study

         14. Contraindications to safe use of metformin, including planned radiologic or
             angiographic study requiring contrast within one week of the study completion

         15. Objection to taking metformin

         16. Participation in any other interventional study during the study duration

         17. Use of nicotine-containing products, including inhaled, chewed, or patches during the
             study.

         18. Use of drugs of abuse.

         19. Restrictions that prevent adherence to standardized meals or unwillingness to adhere
             to a pre-specified meal plan, including abstinence from alcohol and limitation of
             caffeine intake to one drink daily.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey Walford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2014</study_first_submitted>
  <study_first_submitted_qc>July 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Geoffrey Walford, MD</investigator_full_name>
    <investigator_title>Instructor in Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Tryptophan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

